SCHEDULE: Janus Henderson Discloses 1.9% Stake in Avadel Pharma

Janus Henderson Group plc reported a 1.9% beneficial ownership stake in Avadel Pharmaceuticals PLC, holding 1,823,865 ordinary shares as of December 31, 2025.

Summary

• Janus Henderson Group plc (JHG) reported beneficial ownership of 1,823,865 ordinary shares of Avadel Pharmaceuticals PLC.
• This represents 1.9% of Avadel Pharmaceuticals PLC's outstanding ordinary shares.
• The shares are held by various Asset Managers under JHG's ultimate parentage, exercising investment and/or voting discretion on behalf of their clients (Managed Portfolios).
• JHG disclaims ownership associated with dividends or proceeds from the sale of these securities, as these rights belong to the Managed Portfolios.
• The filing is an Amendment No. 7 to a Schedule 13G, indicating a routine update to a previously reported stake.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Avadel Pharmaceuticals PLC.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-slightly positive filing, as it confirms continued institutional interest in Avadel Pharmaceuticals PLC without any negative surprises or changes in investment intent.

Positives

• Janus Henderson Group plc, a significant investment manager, maintains a stake in Avadel Pharmaceuticals PLC, indicating continued institutional interest.
• The filing confirms the shares are held in the ordinary course of business, not for the purpose of changing or influencing control, suggesting a passive investment strategy.

Negatives

• The reported stake of 1.9% is below the 5% threshold, meaning Janus Henderson Group plc does not hold a significant controlling interest in Avadel Pharmaceuticals PLC.

Risks

• The Asset Managers disclaim beneficial ownership of dividends and sale proceeds, meaning their economic interest is indirect through client management.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Avadel Pharmaceuticals PLC. It reflects Janus Henderson Group plc's passive investment position as of the reporting date.

Management Comments

• Kristin Mariani, Head of North America Compliance for Janus Henderson Group plc, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Avadel Pharmaceuticals PLC.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership stakes, which can signal institutional confidence or a routine portfolio allocation within the pharmaceutical sector. A 1.9% stake is a passive position, typical for large asset managers like Janus Henderson, and does not suggest activist intent.

Comparison to Industry Standards

• A 1.9% stake is a standard passive investment size for a large asset manager like Janus Henderson Group plc, which manages a diverse range of client portfolios. This level of ownership is common across the pharmaceutical industry for institutional investors who seek exposure without engaging in corporate governance or control. For instance, similar passive stakes are often seen in companies like Pfizer or Johnson & Johnson, where large funds hold positions for diversification and market exposure rather than strategic influence.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder, potentially reinforcing confidence in the stock's institutional backing.
• Management: No direct impact on management or operations, as the stake is passive and not for control.

Next Steps

• Janus Henderson Group plc will continue to monitor its beneficial ownership in Avadel Pharmaceuticals PLC and file amendments as required by SEC regulations.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of a passive institutional ownership stake and does not provide new information that would warrant a change in investment recommendation. It confirms Janus Henderson Group plc's continued, non-controlling interest in Avadel Pharmaceuticals PLC, suggesting a 'hold' position for investors awaiting more substantive operational or financial news from the company.

Keywords

Avadel Pharmaceuticals, Janus Henderson Group, Schedule 13G, Beneficial Ownership, Ordinary Shares, Institutional Investment, Pharmaceuticals, Investment Management